Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma

March 31, 2015
PDF Version
Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA<font size="-1"><sup>®</sup></font> (pembrolizumab) in Lung Cancer and Melanoma